Bayer AGXSWX:BAYN 35 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 810 Drug Manufacturers companies, Bayer AG ranks worse than 90.12% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bayer AG's Debt-to-Equity or its related term are showing as below:
XSWX:BAYN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.36 Med: 1.2 Max: 1.41
Current: 1.26
During the past 13 years, the highest Debt-to-Equity Ratio of Bayer AG was 1.41. The lowest was 0.36. And the median was 1.20.
XSWX:BAYN's Debt-to-Equity is ranked worse than 90.12% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XSWX:BAYN: 1.26
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bayer AG Debt-to-Equity Related Terms
Bayer AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bayer AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bayer AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bayer AG and its competitors. Over the past decade, Bayer AG's Debt-to-Equity has ranged from 0.36 to 1.41. According to the industry distribution chart, Bayer AG ranks #730 out of 810 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Bayer AG's Debt-to-Equity too high?
Bayer AG's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 1.41. Based on the distribution chart, Bayer AG ranks #730 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #730 out of 810 companies for Debt-to-Equity. This places Bayer AG in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Historically, Bayer AG's own Debt-to-Equity has ranged from 0.36 to 1.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF48.57 — trading 96.9% above its estimated fair value. The current Debt-to-Equity is 0.00. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF48.57 is trading 96.9% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Debt-to-Equity: 0.00
GF Value™: CHF24.67 vs. price of CHF48.57 (96.9% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
